Hls Therapeutics (TSE:HLS) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
HLS Therapeutics reported a decline in their Q1 2024 financial results with revenue at $12.5 million, alongside a significant decrease in royalty revenues. Despite a 54% increase in Vascepa unit demand and a 112% rise in consistent prescribers, CEO Craig Millian announced the end of a promotional agreement with Pfizer and expressed the need for bold action to achieve profitability for Vascepa by year-end.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue